Study of a new medicine for long QT syndrome types 2 and 3
Part of Genetic & congenital, Heart & circulation clinical trials.
This study tests a new medicine called THRV-1268 to see if it can safely improve heart rhythm in people with Long QT syndrome types 2 and 3. It may help reduce the risk of dangerous heart rhythm problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 years or older.
- You have a confirmed genetic diagnosis of Long QT syndrome type 2 or type 3.
- Your most recent ECG shows a QT interval (a measure of heart rhythm) between 480 and 600 milliseconds.
- You have not had a cardiac arrest, ICD implantation, or fainting spell due to an irregular heartbeat in the past month.
- You do not have other significant heart conditions, active liver disease, cancer, or advanced lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral drug to see how it affects the heart's rhythm in healthy adults. It helps make sure the drug is safe before it's tested in patients.
This study looks at how physical activity and exercise capacity affect people with a heart rhythm condition called congenital long QT syndrome. It may help you understand safe ways to stay active and improve your heart health.
This study uses your blood or genetic information to make “iPS cells,” lab-grown cells that can help researchers study inherited heart rhythm problems like LQTS, Brugada syndrome, CPVT, or early repolarization syndrome. It may help improve understanding of why these rhythms happen and guide future treatments.
This study tests whether wearable devices can help monitor Long QT Syndrome, a heart condition. It aims to make tracking your heart easier and more convenient than clinic visits.
This study tests a single dose of a new tablet medication (called TRTL-729) in healthy adults. It helps researchers learn how the drug is absorbed and tolerated, which is a first step in developing a treatment.
This study is evaluating a new diagnostic test for Calcium Release Deficiency Syndrome (CRDS) and related heart rhythm disorders. It aims to find out if this test can accurately identify patients with these conditions, which could lead to better diagnosis and treatment.
Hear when a new Long QT Syndrome (LQTS) 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.